---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-25-000030"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:42:13.189565+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs Q1 net loss $13.7M, cash $60.9M; SL-325 IND filing expected Q3 2025

## Summary
- Net loss of $13.7M ($0.27 per share) for Q1 2025 compared to $18.5M ($0.37 per share) in Q1 2024.
- Cash and equivalents of $60.9M as of Mar 31, 2025, expected to fund operations into 2027.
- SL-325 IND filing expected in Q3 2025; Phase 1 SAD portion first patient in Q3 2025, enrollment complete Q2 2026.
- R&D expenses decreased to $9.9M from $16.3M YoY; G&A expenses decreased to $4.5M from $4.9M.
- Wind-down activities for discontinued oncology programs substantially completed.

## SEC filing metadata
- accession: 0001680367-25-000030
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036725000030/0001680367-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036725000030/sttk-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-25-000030
- JSON: https://secwatch.observer/filing/0001680367-25-000030.json
- Plain text: https://secwatch.observer/filing/0001680367-25-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.